Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-401 + Azacitidine +/- Venetoclax in AML, BPDCN, and High-Risk MDS
NCT03113643Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2017
- Primary completion
- Sep 2021
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, open-label trial of tagraxofusp in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Jun 2017; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NCT03113643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113643.